A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C Richard KimAlexis D. LealJames M. Cleary Original Article Open access 04 February 2023 Pages: 291 - 300
Correction to: A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C Richard KimAlexis D. LealJames M. Cleary Correction Open access 26 March 2023 Pages: 301 - 301
Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways Xuerun PengJianyou ShiLei Zhong Original Article 20 March 2023 Pages: 303 - 315
A prospective feasibility study of uracil–tegafur and leucovorin as adjuvant chemotherapy for patients aged ≥ 80 years after curative resection of colorectal cancer, the HiSCO-03 study Hiroshi OkudaManabu ShimomuraHiroshima Surgical Study Group of Clinical Oncology (HiSCO) Original Article 22 March 2023 Pages: 317 - 324
Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis Joanna BaumDaniel ZicklerJalid Sehouli Original Article Open access 22 March 2023 Pages: 325 - 330
Impact of pre-hydration duration on high-dose methotrexate induced nephrotoxicity in childhood acute lymphoblastic leukaemia in resource constraint centers: a randomized crossover study Sanjeev KheraDeepti MahajanSandeep Dhingra Original Article 23 March 2023 Pages: 331 - 336
Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma Laurence LegrosAlina PascaleOlivier Rosmorduc Original Article Open access 24 March 2023 Pages: 337 - 344
A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy Mohammed El-SadoniSofian Al ShboulTareq Saleh Original Article 24 March 2023 Pages: 345 - 360
